Related by context. All words. (Click for frequent words.) 73 ASCO Abstract 68 Sipuleucel T 68 SABCS 66 Randomized Phase 66 ASH Abstract 66 randomized controlled Phase 65 HCV SPRINT 65 ongoing Phase 1b 65 Phase Ib study 65 pharmacokinetic PK study 65 solithromycin 64 www.asco.org 64 viral kinetic 63 ELACYT 63 TLR antagonist 63 ASCO Annual Meeting 63 ASCO Accepted Abstract 63 Initiated Phase 63 fosbretabulin 63 S#.# [006] 63 ORAL Sync 63 perifosine KRX 63 dose escalation clinical 63 enzastaurin 63 ZACTIMA 63 ASCO GI 63 Aflibercept 62 IMPACT DCM 62 R roscovitine 62 trastuzumab DM1 T DM1 62 GOUT 62 Quinamed 62 Pemetrexed 62 neratinib 62 XL# SAR# 62 Phase 1a clinical 62 Late Breaker 62 Phase 2b Study 62 teriflunomide 62 non nucleoside inhibitor 62 assessing T DM1 62 elotuzumab 62 BRIM2 62 Abstract Number 62 Aplidin R 62 brivanib 62 sipuleucel T 62 Phase #/#a trial 62 Gastrointestinal Cancers Symposium 62 GW# [003] 62 PROSTVAC ® 62 HIMSS Booth 61 EXPAREL ™ 61 ganetespib 61 Doxil ® 61 evaluating Vectibix 61 YONDELIS 61 relapsed MCL 61 Phase 2a clinical 61 CIMZIA TM 61 alvespimycin 61 MAGE A3 ASCI 61 EOquin TM 61 vidofludimus 61 Prostate AdenoCarcinoma Treatment 61 Pharmacokinetic PK 61 SUCCEED trial 61 multicenter Phase 61 PROSTVAC TM 61 Zarnestra 61 Tesetaxel 61 AVOREN 61 phase IIIb 61 trastuzumab emtansine T DM1 61 LUX Lung 61 liposome injection 61 CRLX# 61 Enzastaurin 61 BCIRG 61 Cimzia ® certolizumab pegol 61 anticancer compound 61 Aplidin 61 entitled Synergistic 61 metastatic CRC 61 Natalizumab 61 prucalopride 61 Degarelix 61 www.novelos.com 60 IFN α 60 motesanib diphosphate 60 ROCKET AF 60 Phase III ALLEGRO 60 Phase III randomized controlled 60 NIH Publication 60 Dose Escalation 60 ON #.Na 60 EBMT criteria 60 CIMZIA TM certolizumab pegol 60 NO# [002] 60 RE LY trial 60 Hematology ASH Annual Meeting 60 Vitaxin 60 Archexin 60 recurrent glioblastoma multiforme 60 ENESTnd 60 HORIZONS AMI trial 60 TRANSFORMS 60 BR.# 60 TASKi2 60 Elagolix 60 galiximab 60 mertansine 60 HuMax CD4 60 pan HDAC inhibitor 60 preclinical efficacy 60 www.nejm.org 60 Randomized Phase II 60 subanalysis 60 Phase 2b monotherapy 60 Traficet EN 60 Safinamide 60 Product Monograph 60 HuMax EGFr 60 novel histone deacetylase 60 PEG SN# 60 bortezomib refractory 60 Clinicaltrials.gov 60 Phase 2a trial 60 Glufosfamide 60 #th Annual Interscience 60 SIR Spheres 60 INCB# [002] 60 relapsed refractory multiple myeloma 60 PEG IFN 60 vinorelbine tartrate 60 PI3K/Akt pathway inhibitor 60 KRAS status 60 Solorel TM 60 NSABP B 60 Carfilzomib 60 Antiviral Therapy 60 phase IIb clinical 60 ToGA 60 CCX# 60 Phase Ib II 60 randomized Phase III 59 refractory multiple myeloma 59 BRIM3 59 cetuximab Erbitux 59 ASH Annual Meeting 59 CR# vcMMAE 59 seliciclib CYC# 59 HER2 positive metastatic breast 59 Sandostatin R 59 oral ridaforolimus 59 histone deacetylase HDAC inhibitor 59 Environ Health Perspect 59 Tesmilifene 59 liposomal formulation 59 Phase Ib clinical 59 florbetaben 59 Diabetic Macular Edema DME 59 BiTE antibody MT# 59 depsipeptide 59 Multiple Myeloma MM 59 multicenter randomized Phase 59 SPRYCEL ® 59 CD# [004] 59 Ambrisentan 59 oral diclofenac 59 cEVR 59 Fulvestrant 59 XmAb# 59 alemtuzumab Campath 59 Davis Bintliff 59 aurora kinase 59 plus DOXIL 59 phase IIb study 59 MERIT ES 59 PROTECT AF 59 Pharmacokinetics PK 59 antibody blinatumomab MT#/MEDI-# 59 Clinical Oncology Annual Meeting 59 RADIANT 59 ZOLINZA 59 Phase III AFFIRM 59 brivaracetam 59 Randomized Double blind 59 SCCHN 59 prospective multicentre 59 mso bidi language 59 huC# DM4 59 Oral Fingolimod 59 AASLD Meeting 59 phase 2a 59 BIBW 59 Clinical Trial Results 59 PROVENGE sipuleucel T 59 Dacogen injection 59 Aurora Kinase 59 Epirubicin 59 AVADO 59 ORENCIA ® 59 verteporfin 59 LymphoStat B TM 59 LibiGel ® 59 IMPACT IMmunotherapy 59 XYOTAX TM 59 oral JAK1 59 recurrent GBM 59 pharmacokinetics PK 59 BiTE R 59 Onrigin 59 PSMA ADC 59 Amrubicin 59 Janus Kinase 59 Pertuzumab 59 phase IIb trial 59 Tanespimycin 59 Virulizin ® 59 sorafenib Nexavar 59 achieved CCyR 58 DDP# 58 compound AEZS 58 KRN# 58 Liposomal 58 viral kinetics 58 triciribine phosphate monohydrate 58 R# #mg BID 58 EORTC 58 APPRAISE 58 Phase III VISTA 58 http:/www.ncbi.nlm.nih.gov/pubmed/# 58 mRCC 58 pharmacokinetic PK 58 ZYBRESTAT TM 58 EVEREST II 58 RezularTM 58 ASTEROID 58 EORTC NCI AACR Symposium 58 Brentuximab Vedotin SGN 58 journal Oncogene 58 RE LY 58 huN# DM1 58 mCRC patients 58 Preclinical Study 58 Phase #b/#a clinical 58 elacytarabine 58 Selective Cardiac Myosin Activator 58 PERSEUS 58 AEZS 58 Diabetologia 58 HCV Genotype 58 Velcade bortezomib 58 cabozantinib 58 Cochrane Database Syst Rev 58 MEND CABG 58 NCIC CTG 58 MGd 58 Hormone Refractory Prostate Cancer 58 Br J Cancer 58 sunitinib malate 58 JNCI 58 Temsirolimus 58 PegIFN RBV 58 NMIBC 58 Arch Neurol 58 Atiprimod 58 randomized discontinuation trial 58 REG2 58 gefitinib Iressa 58 Nexavar sorafenib 58 LENALIDOMIDE 58 ExTRACT TIMI 58 DUROS 58 ANN INTERN MED 58 www.thelancet.com 58 gemcitabine Gemzar 58 Xanafide 58 PCI ExTRACT TIMI 58 pertuzumab 58 2m Bryce Vowan 58 forodesine 58 sorafenib tablets 58 HDAC Inhibitor 58 Targretin 58 VeriStrat 58 Vernakalant 58 Decitabine 58 Pharmacokinetic Study 58 registrational Phase 58 ONCONASE ranpirnase 58 Hedgehog Pathway Inhibitor 58 RECIST Response Evaluation Criteria 58 multicenter Phase II 58 resected pancreatic cancer 58 multicenter randomized controlled 58 EndoTAG TM -1 58 OncoVEX GM CSF 58 Hycamtin ® 58 annexin 58 proteasome inhibitor 58 J Clin Oncol 58 tanespimycin 58 metastatic hormone refractory 58 alfa 2a 58 AACR NCI EORTC 58 rALLy 58 AACR Accepted Abstract 58 Poster Discussion 58 Zybrestat 58 Ann Intern Med 58 Novel Oral 58 Genasense ® 57 CALGB 57 ADA Scientific Sessions 57 Hedgehog pathway inhibitor 57 multicenter randomized placebo controlled 57 RAV# 57 Parathyroid Hormone 57 Pharmacodynamic 57 multicentre randomized 57 HDL Selective Delipidation 57 TRO# 57 Silodosin 57 clevidipine 57 phase Ib 57 BrachySil TM 57 controlled multicenter Phase 57 www.hematology.org 57 phase IIa clinical 57 Metastatic Melanoma 57 ILLUMINATE 57 AZILECT R 57 DASISION 57 CALGB # [002] 57 Arch Intern Med 57 Rigel R# 57 #:#-# [031] 57 delafloxacin 57 Valopicitabine 57 ALB # 57 Phase 1b clinical trials 57 metastatic castration resistant 57 Peginterferon 57 Bortezomib 57 Eur J Neurol 57 oral prodrug 57 PROactive study 57 gastrointestinal stromal tumors GIST 57 axitinib 57 Genta Incorporated OTCBB GETA 57 Cloretazine ® 57 Sprycel dasatinib 57 radezolid 57 Kamada AAT 57 Gastrointestinal Stromal Tumors 57 Combination REOLYSIN R 57 recurrent glioma 57 amrubicin 57 Double Blind Randomized 57 mouse xenograft models 57 sfgate.com chronicle submissions 57 varespladib 57 Monoclonal antibody 57 ACZ# 57 Tumor Response 57 label multicenter Phase 57 Diabetic Neuropathy 57 Phase 2b Clinical Trial 57 Phase 2b trial 57 Kevetrin ™ 57 Kahalalide F 57 SPIRIT IV 57 CLARITY study 57 ECASS 57 RECORD1 57 ENMD # 57 NASDAQ CXSP announced 57 ASBMR 57 terlipressin 57 Bayer HealthCare Onyx Pharmaceuticals 57 Pooled Analysis 57 dose escalation trial 57 farletuzumab 57 tramiprosate Alzhemed TM 57 OncoVEX 57 MERLIN TIMI 57 ID NCT# 57 Phase 1b 57 J Natl Cancer Inst 57 ACTEMRA TM 57 FOLOTYN ® 57 AEG# 57 Levoleucovorin 57 Denufosol 57 thalidomide Thalomid 57 PreCISe 57 lumiliximab 57 ixabepilone 57 LEVADEX ™ 57 phase IIb 57 lexidronam injection 57 Tyrosine Kinase Inhibitor 57 vascular disrupting agents 57 CLL SLL 57 BMS# 57 murine model 57 When creating lolterizt 57 Azedra 57 BRAF inhibitor 57 preclinical pharmacokinetic 57 PI3K inhibitor 57 JAK Inhibitor 57 RE LY ® 57 Ixempra 57 CAELYX 57 See CLINICAL PHARMACOLOGY 57 Arimidex anastrozole 57 Keppra XR 57 Meets Primary Endpoint 57 metastatic renal cell carcinoma 57 LymphoStat B belimumab 57 Bosutinib 57 neoadjuvant treatment 57 Arch Surg 57 immunoconjugate 57 HORIZONS AMI 57 targeted antifolate 57 Solid Tumors 57 IMGN# 57 prospective nonrandomized 57 lintuzumab 57 CTAP# Capsules 57 inhibitor RG# 57 Clinical Oncology JCO 57 multiple myeloma MM 57 Phase 1b trial 56 Guanilib 56 Histologic 56 XL# XL# XL# 56 Placebo Controlled Study 56 Factor VIIa 56 Inhalation Solution 56 IL# PE#QQR 56 REMINYL ® 56 durable pain palliation 56 OSV Newbuild Program 56 peginterferon alpha 56 Tezampanel 56 decitabine 56 Hsp# Inhibitor 56 TTB Newbuild Program 56 TG MV 56 TMC# C# 56 malignant pleural mesothelioma 56 ENDEAVOR III 56 transthyretin TTR mediated amyloidosis 56 Arch Dermatol 56 Folfox 56 LibiGel testosterone gel 56 mg administered orally 56 randomized Phase IIb 56 JAK1 56 Erlotinib 56 PARTNER Trial 56 Phase #/#a 56 orally inhaled migraine 56 EGS# 56 metastatic malignant 56 CHAMPION PCI 56 JAK inhibitor 56 Antitumor Activity 56 novel VDA molecule 56 omacetaxine mepesuccinate 56 Dendreon Provenge 56 Darusentan 56 Antiviral Activity 56 cediranib 56 Phase IIb III 56 interferon gamma 1b 56 TO AVOID PREGNANCY WHILE 56 AIR2 Trial 56 ThermoDox ® clinical 56 Elitek 56 ORMD 56 Hematology Annual Meeting 56 refractory metastatic 56 Teriflunomide 56 Pharmaprojects 56 multicenter clinical 56 mITT population 56 EZN 56 novel oral anticoagulant 56 Romiplostim 56 OXi# 56 placebo controlled clinical 56 Kinase Inhibitor 56 Bioenvision Nasdaq BIVN 56 http:/www.hematology.org 56 Society CTOS 56 Molecular Cancer 56 Cochrane Database Syst Rev. 56 Pegylated Liposomal Doxorubicin 56 Suppl. 56 xenograft models 56 tipranavir ritonavir 56 CRMD# 56 Muraglitazar 56 Cardiotoxicity 56 Initiate Phase 56 Clinical Antipsychotic Trials 56 Phase IIb Trial 56 HQK 56 CR CRu 56 CR nPR 56 rALLy trial 56 longitudinal observational study 56 aflibercept 56 Thymosin 56 ABCSG 56 Pemphigus Vulgaris 56 humanized interleukin 6 56 KSP inhibitor 56 midstage clinical 56 SYN# 56 CORD II 56 Sym# 56 CRp 56 PXD# 56 DCVax R 56 PIX# [002] 56 Spiegelmer ® 56 vascular disrupting agent 56 #-# Full Text 56 Dasatinib 56 observational cohort study 56 Hepatocellular Carcinoma 56 IRX 2 56 J Clin Endocrinol Metab 56 Zenvia Phase III 56 ChronVac C R 56 RIBBON 56 SUTENT ® 56 efavirenz EFV 56 randomized Phase 2b 56 ASCO GU 56 J Nerv Ment Dis 56 tumor specific antigen 56 dasatinib Sprycel 56 trastuzumab DM1 56 ThermoDox R 56 Immunogenicity 56 CLORETAZINE TM VNP#M 56 pain palliation 56 ACUITY trial 56 abstr 56 #F FDG PET 56 Dalbavancin 56 Phase IIB 56 RE SURGE 56 etanercept Enbrel 56 Ceflatonin R 56 Carotid Revascularization Endarterectomy vs. 56 masitinib 56 VNP#M 56 BZL# 56 ALN TTR 56 adecatumumab 56 LT NS# 56 Randomized Phase III 56 resolvin 56 ICAAC IDSA 56 Neuvenge 56 NASDAQ OMER 56 Omacetaxine 56 platinum refractory 56 SAR# [004] 56 Nasdaq IDRA 56 Receptor Antagonists 56 Severe Sepsis 56 Biological Therapy 56 PANVAC VF 56 Antigenics QS 56 trabectedin 56 CCR5 antagonist 55 seliciclib 55 standard chemotherapy regimen 55 Interferon alfa 55 NP2 Enkephalin 55 CELGENE 55 DermaVir Patch 55 PEGylated interferon 55 #:#-# [033] 55 USpella 55 deforolimus 55 Am J Gastroenterol 55 DASISION study 55 oral FTY# 55 HGS# 55 refractory chronic lymphocytic 55 EINSTEIN DVT 55 miRview mets 55 Vandetanib 55 Acute Ischemic Stroke 55 non nucleoside HCV 55 Squalamine 55 Full Prescribing Information 55 CoFactor 55 Schizophrenia Bulletin 55 Allovectin 7 55 Anticancer Drugs 55 Clinical Trial Data 55 Treated Patients 55 Anti CD# Antibody 55 CTRC AACR San Antonio 55 AACR San Antonio 55 HyQ 55 evaluating tivozanib 55 INCB# [001] 55 prospective randomized multicenter 55 IKK epsilon 55 HCV NS5B polymerase 55 palifosfamide 55 Telaprevir 55 miRview TM mets 55 clinicaltrials.gov 55 BAL# [002] 55 Phase Ib Clinical Trial 55 p# biomarker 55 Clinical Therapeutics 55 TACI Ig 55 MAb 55 receptor modulators 55 ACS Chemical Biology 55 paclitaxel carboplatin 55 nd Annual Meeting 55 Lucanix 55 Developmental Therapeutics Immunotherapy 55 ICAAC 55 iclaprim 55 mso ansi language 55 PKC# 55 Medicinal Chemistry Letters 55 Phase 2a Trial 55 RhuDex 55 vitro cytotoxicity 55 AKT inhibitor 55 relapsed multiple myeloma 55 Hematological Malignancies 55 Achieves Primary Endpoint 55 maturation inhibitor 55 trastuzumab Herceptin ® 55 RTOG 55 trastuzumab Herceptin 55 DOSAGE AND ADMINISTRATION 55 metastatic renal cell 55 RE MODEL 55 FDA Approvable Letter 55 regorafenib 55 number NCT# ClinicalTrials.gov 55 efalizumab 55 velafermin 55 AAG geldanamycin analog 55 sunitinib Sutent 55 nanopharmaceutical 55 Tasigna nilotinib 55 oral renin inhibitor 55 JAK2 inhibitor 55 AACR Meeting 55 Vidaza azacitidine 55 AACR #st Annual Meeting 55 including eniluracil ADH 55 II Clinical Trial 55 Trofex 55 Romidepsin 55 FASEB J. 55 ENDEAVOR IV 55 Bruton tyrosine kinase Btk 55 Dacogen TM 55 antiangiogenic agent 55 recurrent metastatic 55 Phase 2a 55 targeting CD# 55 ponatinib 55 AMEX RGN 55 Ranolazine 55 Pulmonary Arterial Hypertension 55 ® cetuximab 55 YERVOY 55 Cloretazine R 55 romidepsin 55 neovascular diseases 55 Sapacitabine 55 ErbB2 positive 55 orally dosed 55 Orazol 55 HuMax 55 evaluating carfilzomib 55 anti angiogenic therapy 55 article #.#/NEJMoa# 55 rALLy clinical trial 55 irreversible inhibitor 55 MEND CABG II 55 Efficacy Results 55 Talabostat 55 Rebif ® 55 AVASTIN 55 sargramostim 55 selective orally bioavailable 55 journal Lancet Neurology 55 CYT# 55 Percutaneous Tibial Nerve Stimulation 55 TAXOTERE R 55 satraplatin Phase 55 EGFR HER2 55 DiLA2 55 NCCTG N# 55 AZILECT ® 55 ACCLAIM 55 Glypromate 55 EORTC NCI AACR 55 orally administered inhibitor 55 TASKi3 55 Allovectin 7 ® 55 Vicriviroc 55 Am J Epidemiol 55 JBJS 55 BLOSSOM 55 doi #.#/fj.#-# 55 recurrent malignant glioma 55 Raptiva ® 55 Aggressive Reduction 55 ATTRACT 55 DCCR 55 ISEL 55 ug dose 55 MT# MEDI 55 CAMMS# 55 Trandolapril 55 BARI 2D 55 TAXUS IV 55 Subgroup analysis 55 Fibrocell 55 Epilepsia 55 Avanafil 55 Epratuzumab 55 Xelox 55 aminolevulinic acid ALA 55 BioMarck 55 Advexin 55 immunotherapeutic agent 55 Deforolimus 55 Controlled Release 55 CROI 55 Intervention Effectiveness 55 SGLT 55 Propagation Forecast Bulletin 55 PROLARIS 55 Angiolix 55 AP# [003] 55 essential thrombocythemia ET 55 CYT# potent vascular disrupting 55 Faslodex 55 information portal www.#.com 55 Glatiramer acetate 55 zanolimumab 55 panobinostat 55 nucleoside analog 55 GFT# 55 VAX# 54 antisense inhibitor 54 Arch Pediatr Adolesc Med 54 GRN#L 54 Lenalidomide 54 LUMINATE 54 Randomized Evaluation 54 glufosfamide 54 Prospective Randomized 54 Panzem R NCD 54 AACR #nd Annual Meeting 54 Gynecol Oncol 54 Oncogene 54 multicenter prospective 54 Glatiramer Acetate 54 colesevelam HCl 54 Taxotere ® 54 Clinical Trials Update 54 HIF PHI 54 tipranavir r 54 Poster Presentation 54 Candesartan 54 nucleotide analog 54 figitumumab 54 heFH 54 bispecific antibody 54 Podium Presentation 54 BMC Musculoskeletal Disorders 54 Interferon Gamma 54 SPIRIT FIRST 54 Obes Res 54 DAS# Fludase ® 54 biologic DMARD 54 generation antisense 54 Actelion Pharmaceuticals Ltd 54 Diabetic Nephropathy 54 novel synthetic peptide 54 preclinically 54 Randomised 54 metastatic HRPC 54 www.annals.org 54 perifosine 54 Successfully Completes Phase 54 Symadex 54 Nasdaq REGN 54 Fingolimod 54 Avastin bevacizumab 54 Placebo Controlled Trial 54 talabostat 54 ATAC Arimidex Tamoxifen Alone 54 RhuDex TM 54 systemic RNAi therapeutic 54 eltrombopag 54 AstraZeneca Targacept 54 NASDAQ CYTK announced 54 Removab 54 mitogen activated ERK kinase 54 Randomized controlled 54 brentuximab vedotin SGN 54 pharmacodynamic PD 54 Topline Results 54 CenterWatch Monthly 54 Hodgkin lymphoma HL 54 Eur Urol 54 NPC 1C 54 ANTEGREN 54 selective antagonist 54 HuMax HepC 54 Afinitor everolimus 54 genitourinary cancers 54 Stent Restenosis 54 PTK ZK 54 Novel Antibiotic 54 Gleevec resistant 54 Apoptone 54 NEJM.org 54 mso fareast language 54 Chronic Hepatitis C 54 CCR2 54 Genitourinary Cancers Symposium 54 Immunohistochemical analysis 54 histone deacetylase inhibitor 54 Estrogen Receptor 54 CLL8 54 Cimzia TM 54 Ann Oncol 54 oral proteasome inhibitor 54 Nilotinib 54 boosted protease inhibitor 54 Annual Interscience Conference 54 ImmunoVEX HSV2 54 metastatic neuroendocrine tumors 54 OMP #M# 54 novel immunotherapeutic 54 Obstet Gynecol 54 Cancer Incidence Mortality 54 CAMPATH 54 Nasdaq IDRA today 54 Oral Presentation 54 prospective multicenter study 54 www.oxigene.com 54 Biol Psychiatry 54 ritonavir boosted 54 angiogenesis inhibitor 54 STRIDE PD 54 Bazedoxifene 54 Chronic Lymphocytic Leukemia 54 Eur J Endocrinol 54 selective adenosine 54 ARBITER 54 brand eszopiclone 54 Sunesis Pharma 54 PREDICTIVE 54 Am Fam Physician 54 INGN 54 Systemic Delivery 54 isoform selective 54 riociguat 54 entinostat 54 HER2 positivity 54 Blinatumomab 54 Semafore Pharmaceuticals 54 Investigational Compound 54 Zactima 54 ATL# [001] 54 OHR/AVR# 54 OncoVex 54 #nd EORTC NCI 54 5 HT2C receptor 54 selective inhibition 54 PDE4 inhibitor 54 anti angiogenic agent 54 Randomized Study 54 Study Evaluating 54 OPAXIO 54 Controlled Trial 54 CEQ# 54 eniluracil 54 ® pioglitazone HCl 54 Teysuno 54 ISTODAX ® 54 comparing alemtuzumab 54 Cardiac Allograft Rejection 54 epoetin alpha 54 Anavex #-# 54 ACCORD Lipid 54 Myelodysplastic Syndrome MDS 54 morphometric vertebral fractures 54 advanced hepatocellular carcinoma 54 Chicago Multidisciplinary Symposium 54 Soft Tissue Sarcoma 54 Pivotal Phase III 54 recurrent glioblastoma 54 ara C 54 MBRX 54 telcagepant 54 EuroIntervention 54 Phase 2b Trial 54 prospectively randomized 54 rosuvastatin Crestor 54 Radezolid 54 Proxinium TM 54 azacytidine 54 Olmesartan 54 AHA Scientific Sessions 54 UroVysion 54 DRAFT PICKS 1st 54 Omnitarg 54 GV# [001] 54 Multiple Ascending Dose 54 Advanced Renal Cell 54 pharmacokinetic characteristics 54 ARRY # 54 ProSavin 54 Bicalutamide 54 Molecular Therapy 54 Cancer Res 54 Human Mutation 54 Fibrin Patch 54 Plicera 54 Exenatide Byetta 54 K ras mutations 54 OVATURE trial 54 Tarvacin 54 immunotherapeutic vaccine 54 Nasdaq ACHN 54 pediatric acute lymphoblastic 54 NEUVENGE 54 vismodegib 54 AFRS TM 54 Philadelphia Chromosome Positive 54 EURIDIS 54 generation purine nucleoside 54 bortezomib Velcade 54 Preclinical Models 54 Bendavia 54 Phase III HEAT 54 Allogeneic 54 dual endothelin receptor antagonist 54 antisense oligonucleotide 54 AASLD 54 Btk Inhibitor PCI 54 BY PUBLIC ENEMY 54 Telatinib 54 Prospective Randomized Trial 54 Prospective Multicenter 54 atrasentan 54 Eur J Cancer 54 Phase IIA 54 darinaparsin ZIO 54 FASLODEX 54 BEZ# 54 ONCONASE R 54 Ann Rheum Dis 54 TIMP 1 54 monoclonal antibody mAb 54 Mycophenolate Mofetil 54 Ann Emerg Med 54 TLR9 agonists 54 MOZOBIL 54 AA Amyloidosis 54 mCRC 54 Calcium Acetate 54 #S #S [002] 54 Vitro Activity 54 J Affect Disord 54 PROTEGE 54 #th Interscience Conference 54 Lenocta